×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly ...
PR Newswire
Share this article ... HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023...
8 months ago
Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Simply Wall Street
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.
1 week ago
While institutions invested in 3SBio Inc. (HKG:1530) benefited from last week's 6.9% gain, individual investors stood to ...
Simply Wall Street
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and...
1 month ago
Best Under A Billion 2018: China Drugmaker Struggles To Break Into Europe And North America
Forbes
Lou Jing's drugmaker has gotten a big foothold in China and wants future breakthroughs to be global.
69 months ago
Interferons Market size is set to grow by USD 2.65 bn from 2024-2028, 3SBio Inc., Bayer AG & Biogen Inc., and more to ...
PR Newswire
Notably, SNG001, a new interferon beta-1a treatment, has recently received regulatory approval. The market's expansion is further fueled by the...
1 month ago
3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration
Contract Pharma
3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration ... 3SBio and Verseau Therapeutics have formed a partnership to develop and...
53 months ago
3Sbio licenses out global rights of PD-1 inhibitor to Syncromune
BioWorld MedTech
3Sbio Inc.'s subsidiary, Sunshine Guojian Pharmaceutical Co. Ltd., has licensed out the global rights of its anti-PD-1 antibody candidate,...
27 months ago
AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China
Fierce Pharma
AZ is signing over commercial rights in China to its GLP-1 agonist Byetta (exenatide) and long-acting version Bydureon for $50 million up front,...
90 months ago
3SBio: Firm Hold Over Biopharma
Forbes India
The company was renamed 3SBio and went public on Nasdaq in 2007 as the exchange's first Chinese biopharma firm. It met a lukewarm capital market...
65 months ago
3SBio's Tan on Pipeline products, Opportunities, Regulation
Bloomberg
Bo Tan, chief financial officer at 3SBio, discusses the opportunities he's seeing in China's red-hot healthcare sector, the products in the...
70 months ago